Featured

Gensco Pharma® Acquires Global Rights and IP for RizaFilm® and RizaPort®

Gensco Pharma acquires global rights to RizaFilm® and RizaPort®, with a U.S. migraine treatment launch planned for Q4 2025 and global expansion ahead.

Gensco® Pharma Announces RizaFilm® Commercialization Update in the United States

Gensco® Pharma, a specialty pharmaceutical company, in partnership with IntelGenx is announcing the anticipated launch of RizaFilm® for Q1-2024. RizaFilm® is based on IntelGenx’s proprietary VersaFilm® technology and is patent protected until 2034. As the NDA holder, Gensco® will begin commercialization of the 10mg Film and will continue to fund the expanded indications for the 5mg Pediatric dose.

RizaFilm® is a film formulation of rizatriptan and the only oral dissolvable film available for the treatment of acute migraines. RizaFilm® has ease of convenience and does not require a drink for swallowing, thus allowing for rapid administration and relief from migraine related pain and nausea.

Skin Tears Treatment Market to Observe Strong Development by 2018-2026

[To download a printable version of this article, click here] MARKET RESEARCH April 12, 2019 / kalyani badkas Skin tears have become a common issue among people of older age as the skin becomes more delicate and drier and so skin tears treatment has become an...

Gensco® Pharma Partners with IntelGenx to Launch and Commercialize RIZAFILM® (U.S. market name for RIZAPORT® — Rizatriptin Oral Film) in the United States

Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in development and commercialization of prescription transdermal products, today announced the execution of a definitive licensing, development and supply...

Now Available Through Federal Supply Schedule (FSS)

Contract #V797D-70219 The Only FDA-Approved Prescription Hydrogel and 4% Lidocaine HCl for Pain Associated with Wound Healing and Vasculitis FDA Approved #K092086 Astero®, manufactured by Gensco Pharma, is now available through the Federal Supply Schedule. Astero®...

Physician Explores Gout Treatment Options

As seen in Chain Drug Review | May 15, 2017 MIAMI — Gout is an extremely painful form of inflammatory arthritis and the most common form of this type of arthritis in men, according to Dr. Gary Myerson, a founding fellow of the American College of Rheumatology....